Safety

DEA Controlled Substances

CSCN: 1729
CAS SCH: IV
NARC: N

Hazard and Precautionary Statements (GHS)

Serdexmethylphenidate Chemical Properties,Usage,Production

Uses

Serdexmethylphenidate is part of the composition of Azstarys, which consists of a prodrug/drug co-formulation ofserdexmethylphenidate and dexmethylphenidate in a 70:30 molar ratio. Azstarys is approved by the USFDA for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older. Serdexmethylphenidate consists of pharmacologically active dimethylphenidate attached to the nicotinoyl-L-serine portion via a carboxymethylene linker.

Metabolism

Catabolism of serdexmethylphenidate is believed to occur in the lower gastrointestinal tract. As a result, therapeutic doses of the released dexmethylphenidate do not generally appear until several hours after ingestion. As such, the long-duration action of this prodrug is combined with immediate-release dexmethylphenidate in the marketed combination therapy.